FDA green-lights fall COVID-19 boosters

As the COVID-19 case count continues to tick upward, the US Food and Drug Administration has approved an updated vaccine for use ahead of the northern hemisphere winter. The emergency use authorization covers updated mRNA vaccines from both Pfizer and Moderna.

The booster shots will target the JN.1 and KP.2 strains of SARS-CoV-2, both of which are omicron variants. Last year's booster keyed on omicron subvariant XBB.1.5, which has long since lost the evolutionary arms race.

Both Spikevax (Moderna) and Comirnaty (Pfizer) vaccines have been updated. While the vaccine is targeted toward those 12 and over, children aged six months through 11 years are also eligible for the updated vaccines under the FDA's emergency use authorization.